目次

Contents

1. Executive Summary

2. Global Next-Generation Antibody Therapeutics Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Macro-Economic Indicators

6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8. Recent Development, Policies & Regulatory Landscape

9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10. Global Next-Generation Antibody Therapeutics Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11. Global Next-Generation Antibody Therapeutics Market
11.1. Market Size & forecast, 2019A-2030F
11.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Global Next-Generation Antibody Therapeutics Market: Market Segmentation
12.1. By Regions
12.1.1. North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By Technology: Market Share (2020-2030F)

13. 12.3.1. Antibody-Drug Conjugates (ADCs), By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

14. 12.3.2. Bispecific Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

15. 12.3.3. Antibody Fragments and Antibody-like Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

16. 12.3.4. Fc-engineered Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

17. 12.3.5. Biosimilar Antibody Products, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

18. Company Profile
18.1. Hoffmann-La Roche Ltd.
18.1.1. Company Overview
18.1.2. Company Total Revenue (Financials)
18.1.3. Market Potential
18.1.4. Global Presence
18.1.5. Key Performance Indicators
18.1.6. SWOT Analysis
18.1.7. Product Launch
18.2. Kyowa Hakko Kirin Co. Ltd.
18.3. Seattle Genetics Inc.
18.4. ImmunoGen Inc.
18.5. Bristol-Myers Squibb Company
18.6. Pfizer Inc.
18.7. Amgen Inc
18.8. Biogen
18.9. Xencor Inc
18.10. Other Prominent Players

19. Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.